Risk factors

Total tariff rates on goods imported from China reached 152.5% in 2025, sharply impacting sourcing costs.

Royalty Pharma financing adds debt covenants, collateral restrictions, and repayment risks to Revolution Medicines’ funding profile.

Recursion Pharmaceuticals added risks covering a June 2025 cost reduction plan, workforce cuts, and specific drug patent protections. Intellectual property uncertainty and ESG compliance also feature prominently among new disclosures.

RxSight added risks concerning trade tariffs, artificial intelligence adoption, and a securities class action lawsuit filed in July 2025. Regulatory hurdles and supply chain dependencies remain core operational threats.

Schwab plans expanded digital-asset access, including select cryptocurrency spot trading, beginning in 2026.

Schrodinger faces heightened tariff risks under new trade policies affecting international partners like China and Canada. The company updated its tax loss carryforward figures and added disclosures regarding regulatory disruptions and Orange Book patent challenges.

SolarEdge is restructuring operations, exiting unprofitable markets and battery manufacturing, and grappling with U.S. tax policy changes.

Simmons First National added risks concerning core deposit stability, credit oversight, and tax audits following a major securities portfolio repositioning. Investment securities holdings dropped from $6.17 billion to $3.27 billion as approximately $3.2 billion was sold. Credit card net charge-offs were 2.93% in 2024 and 2.20% in 2023.

Solid Power's risk profile now addresses artificial intelligence integration, expanded equity distribution through an ATM, and specific warrant settlement terms.

International real estate footprint expanded to include Indonesia and China while Klépierre's European footprint dropped to 13 countries. Macroeconomic risk disclosures now explicitly highlight implemented and threatened tariffs alongside retaliatory trade disputes.

SPX Technologies added risks concerning U.S. government contracts and divestiture liabilities from the Crawford acquisition. Macroeconomic risks now explicitly cite tariffs and trade barriers.

The company added risks concerning generative AI tools, CECL credit loss volatility, and expanded disclosures on director personal investment limits. Management addressed office sector valuation declines and clarified tax treatment for infrastructure lending segments.